Data as of Q4 2025 (Dec 31, 2025)

CAXTON CORP

โ€ขCIK: 1388551โ€ขFiling: Q4 2025

**CAXTON CORP** manages a $4M AUM across 11 distinct positions, exhibiting a concentrated, tactical allocation strategy. The fund's largest holding is GQ9, representing $2.8M, while significant allocations are also maintained in BRK/B ($0.4M) and SYRE ($0.3M). The remaining portfolio is diversified across smaller, targeted bets, including BRD1EUR ($0.2M) and KYTX ($0.2M). This structure suggests a focused, high-conviction approach to market opportunities.

Total AUM
$4.3M
QoQ Performance
-81.3%
Positions
11
Top 10 Concentration
99.4%
Latest Filing
Q4 2025

Top Holdings Allocation

GQ9
BRK/B
SYRE
GQ964.5%
BRK/B8.3%
SYRE6.8%
BRD1EUR4.9%
KYTX4.1%
CMPX3.7%
LXEO3.2%
XFOR1.5%

๐Ÿ“ˆ Biggest Buys

SYRE
SPYRE THERAPEUTICS INC
NEW
6.8% of portfolio
XFOR
X4 PHARMACEUTICALS INC
NEW
1.5% of portfolio
BRK/B
BERKSHIRE HATHAWAY INC DEL
+9.1%
8.3% of portfolio
IKT
INHIBIKASE THERAPEUTICS INC
+73.6%
1.4% of portfolio

๐Ÿ“‰ Biggest Sells

BRD1EUR
MIND MEDICINE MINDMED INC
-41.9%
4.9% of portfolio
CMPX
COMPASS THERAPEUTICS INC
-44.9%
3.7% of portfolio
GQ9
SPDR GOLD TR
-4.4%
64.5% of portfolio
KYTX
KYVERNA THERAPEUTICS INC
-18.3%
4.1% of portfolio
LXEO
LEXEO THERAPEUTICS INC
-19.6%
3.2% of portfolio

Sector Breakdown

Other91.7%
Financial8.3%

๐Ÿšช Exited Positionssold since Q3 2025

RZLT
REZOLUTE INC
SOLD
$18.7M
ELVN
ENLIVEN THERAPEUTICS INC
SOLD
$268.1K
BCAX
BICARA THERAPEUTICS INC
SOLD
$172.8K

Changes from Q3 2025

NEW2 new positions
โ†‘2 increased
โ†“6 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023